Kane Biotech (CVE:KNE) Shares Up 8.7% – Here’s What Happened
by Teresa Graham · The Cerbat GemKane Biotech Inc. (CVE:KNE – Get Free Report) rose 8.7% on Tuesday . The company traded as high as C$0.13 and last traded at C$0.13. Approximately 1,000 shares traded hands during trading, a decline of 99% from the average daily volume of 131,581 shares. The stock had previously closed at C$0.12.
Kane Biotech Stock Up 8.7 %
The stock has a market cap of C$16.56 million, a P/E ratio of -4.17 and a beta of 0.52. The firm has a 50 day simple moving average of C$0.14 and a 200-day simple moving average of C$0.14. The company has a quick ratio of 0.39, a current ratio of 0.82 and a debt-to-equity ratio of 1,164.24.
Kane Biotech (CVE:KNE – Get Free Report) last released its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.62 million for the quarter.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Stories
- Five stocks we like better than Kane Biotech
- What is the NASDAQ Stock Exchange?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What is a buyback in stocks? A comprehensive guide for investors
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?